First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report

Thoracic Cancer - Australia
doi 10.1111/1759-7714.13436
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

P3.17-14 a Case of a Patient Harboring an EGFR -T790m Mutation Positive in Squamous Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2019English

P2.01-90 PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients With or Without EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

P3.13-30 Driver Mutation in Heavy Smoker Patient With Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.01 Strong PD-L1 Expression Predicts Poor Response and De Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients With EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Gefitinib for a Poor Performance Status Patient With Squamous Cell Carcinoma of the Lung Harboring EGFR Mutation

Internal Medicine
Internal MedicineMedicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy